Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix

A. P. Kudelka; C. F. Verschraegen; T. Levy; C. L. Edwards; A. Fishman; R. S. Freedman; A. Kaplan; D. G. Kieback; R. Mante; K. Ende; M. Steger; J. J. Kavanagh

doi:10.1097/00001813-199606000-00004

Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix

A. P. Kudelka^*, C. F. Verschraegen, T. Levy, C. L. Edwards, A. Fishman, R. S. Freedman, A. Kaplan, D. G. Kieback, R. Mante, K. Ende, M. Steger, J. J. Kavanagh

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Eighteen patients with squamous cell cancer of the cervix were treated with i.v. docetaxel 100 mg/m² over 1 h every 21 days. No patient received prior chemotherapy, except as a radiation sensitizer. Median age was 42 years (range 30-58) and Zubrod performance states was 1 (0-2). Ten (59%) patients had prior surgery and 11 (65%) had prior radiation therapy. Sixteen patients were evaluable for response. Two patients had a partial response (13%; 95% CI 0-32%) and eight (50%; 95% CI 23-77%) had stable disease. Dose reduction to 75 mg/m² was required in 10 patients and to 55 mg/m² in one patient. Granulocytopenia was the major hematopoietic toxicity (31% grade 3 and 44% grade 4). Docetaxel is active in patients with squamous cell cancer of the cervix and may be tolerable at this dose schedule.

Original language	English
Pages (from-to)	398-401
Number of pages	4
Journal	Anti-Cancer Drugs
Volume	7
Issue number	4
DOIs	https://doi.org/10.1097/00001813-199606000-00004
State	Published - 1996
Externally published	Yes

Keywords

Cervix cancer
Docetaxel
Granulocyte colony stimulating factor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00001813-199606000-00004

Cite this

Kudelka, A. P., Verschraegen, C. F., Levy, T., Edwards, C. L., Fishman, A., Freedman, R. S., Kaplan, A., Kieback, D. G., Mante, R., Ende, K., Steger, M., & Kavanagh, J. J. (1996). Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-Cancer Drugs, 7(4), 398-401. https://doi.org/10.1097/00001813-199606000-00004

@article{73ed0536bf674119b7e8008b2d3a94dd,

title = "Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix",

abstract = "Eighteen patients with squamous cell cancer of the cervix were treated with i.v. docetaxel 100 mg/m2 over 1 h every 21 days. No patient received prior chemotherapy, except as a radiation sensitizer. Median age was 42 years (range 30-58) and Zubrod performance states was 1 (0-2). Ten (59%) patients had prior surgery and 11 (65%) had prior radiation therapy. Sixteen patients were evaluable for response. Two patients had a partial response (13%; 95% CI 0-32%) and eight (50%; 95% CI 23-77%) had stable disease. Dose reduction to 75 mg/m2 was required in 10 patients and to 55 mg/m2 in one patient. Granulocytopenia was the major hematopoietic toxicity (31% grade 3 and 44% grade 4). Docetaxel is active in patients with squamous cell cancer of the cervix and may be tolerable at this dose schedule.",

keywords = "Cervix cancer, Docetaxel, Granulocyte colony stimulating factor",

author = "Kudelka, {A. P.} and Verschraegen, {C. F.} and T. Levy and Edwards, {C. L.} and A. Fishman and Freedman, {R. S.} and A. Kaplan and Kieback, {D. G.} and R. Mante and K. Ende and M. Steger and Kavanagh, {J. J.}",

year = "1996",

doi = "10.1097/00001813-199606000-00004",

language = "אנגלית",

volume = "7",

pages = "398--401",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "4",

}

TY - JOUR

T1 - Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix

AU - Kudelka, A. P.

AU - Verschraegen, C. F.

AU - Levy, T.

AU - Edwards, C. L.

AU - Fishman, A.

AU - Freedman, R. S.

AU - Kaplan, A.

AU - Kieback, D. G.

AU - Mante, R.

AU - Ende, K.

AU - Steger, M.

AU - Kavanagh, J. J.

PY - 1996

Y1 - 1996

N2 - Eighteen patients with squamous cell cancer of the cervix were treated with i.v. docetaxel 100 mg/m2 over 1 h every 21 days. No patient received prior chemotherapy, except as a radiation sensitizer. Median age was 42 years (range 30-58) and Zubrod performance states was 1 (0-2). Ten (59%) patients had prior surgery and 11 (65%) had prior radiation therapy. Sixteen patients were evaluable for response. Two patients had a partial response (13%; 95% CI 0-32%) and eight (50%; 95% CI 23-77%) had stable disease. Dose reduction to 75 mg/m2 was required in 10 patients and to 55 mg/m2 in one patient. Granulocytopenia was the major hematopoietic toxicity (31% grade 3 and 44% grade 4). Docetaxel is active in patients with squamous cell cancer of the cervix and may be tolerable at this dose schedule.

AB - Eighteen patients with squamous cell cancer of the cervix were treated with i.v. docetaxel 100 mg/m2 over 1 h every 21 days. No patient received prior chemotherapy, except as a radiation sensitizer. Median age was 42 years (range 30-58) and Zubrod performance states was 1 (0-2). Ten (59%) patients had prior surgery and 11 (65%) had prior radiation therapy. Sixteen patients were evaluable for response. Two patients had a partial response (13%; 95% CI 0-32%) and eight (50%; 95% CI 23-77%) had stable disease. Dose reduction to 75 mg/m2 was required in 10 patients and to 55 mg/m2 in one patient. Granulocytopenia was the major hematopoietic toxicity (31% grade 3 and 44% grade 4). Docetaxel is active in patients with squamous cell cancer of the cervix and may be tolerable at this dose schedule.

KW - Cervix cancer

KW - Docetaxel

KW - Granulocyte colony stimulating factor

UR - http://www.scopus.com/inward/record.url?scp=8944249284&partnerID=8YFLogxK

U2 - 10.1097/00001813-199606000-00004

DO - 10.1097/00001813-199606000-00004

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 8826607

AN - SCOPUS:8944249284

SN - 0959-4973

VL - 7

SP - 398

EP - 401

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 4

ER -

Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this